How to Switch The transition is straightforward: Stopping Saxenda: No taper required Can stop after last daily dose No withdrawal effects Starting semaglutide: Begin at starting dose (0.25mg weekly) Follow standard titration schedule Some providers start at higher doses for patients switching from other GLP-1s, but standard titration is safest Timing: Can start semaglutide the week after stopping Saxenda No mandatory washout period Some providers start immediately after last Saxenda dose What to Expect During transition: Appetite suppression may temporarily decrease during early semaglutide titration GI side effects may recur as you adjust to new medication Full semaglutide effect takes 4-5 months to reach After transition: Most patients see additional weight loss beyond what Saxenda achieved Weekly dosing is typically more convenient Similar ongoing management Transition Considerations Timing expectations: Dont expect immediate additional weight loss Titration period is necessary even for patients experienced with GLP-1s Full benefit of switch becomes apparent at maintenance doses Managing expectations: Some initial adjustment period is normal The convenience benefit is immediate Weight loss benefit develops over months Practical Considerations for Each Medication Understanding day-to-day use helps set expectations
How to Take Retatrutide Retatrutide is expected to be given once weekly as a subcutaneous injection into the abdomen, thigh or upper arm
GLP-1 medications are designed to bind to cells in your body that have GLP-1 receptors, just like your natural GLP-1 hormone would
If you would rather see the bigger picture of monitored, provider guided care first, explore what medically supervised peptide therapy in Miami actually looks like, from an in person evaluation through a monitored, provider guided treatment plan built around your goals
Research suggests that protein is one of the most effective dietary triggers for GLP-1 release
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drugnaive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
